<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00216164</url>
  </required_header>
  <id_info>
    <org_study_id>HOG LYM03-64</org_study_id>
    <nct_id>NCT00216164</nct_id>
  </id_info>
  <brief_title>Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma</brief_title>
  <official_title>Phase II Study of Rituximab and Gemcitabine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Hoosier Oncology Group LYM03-64</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoosier Cancer Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Walther Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoosier Cancer Research Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rituximab has been demonstrated to sensitize drug-resistant NHL cells to the cytotoxic&#xD;
      actions of several chemotherapy agents by enhancing sensitivity of tumor cells to&#xD;
      chemotherapy-induced apoptosis. Gemcitabine, a nucleoside analog that is used in several&#xD;
      other malignancies, has shown very promising activity in patients with refractory Hodgkin's&#xD;
      disease and low-grade NHL. The combination of rituximab and gemcitabine may have synergistic&#xD;
      cytotoxic action in patients with relapsed or refractory DLBCL and possibly lead to improved&#xD;
      response rates and demonstrable clinical benefit.&#xD;
&#xD;
      This trial will investigate the efficacy the combination of rituximab and gemcitabine in&#xD;
      treating patients with relapsed or refractory DLBCL.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: This is a multi-center study.&#xD;
&#xD;
        -  Rituximab 375 mg/m2 day 1 of 21 day cycle&#xD;
&#xD;
        -  Gemcitabine 1000 mg/m2 days 1 and 8 of 21 day cycle&#xD;
&#xD;
      Subgroup 1. Relapsed after responding to first line chemotherapy, who are not candidates for&#xD;
      salvage high-dose chemotherapy.&#xD;
&#xD;
      Subgroup 2. Failure to achieve a complete response or relapsed after responding to salvage&#xD;
      chemotherapy (any number of salvage regimens allowed), who are not candidates for high-dose&#xD;
      chemotherapy.&#xD;
&#xD;
      Subgroup 3. Refractory to first line chemotherapy and/or 1 (one) salvage chemotherapy&#xD;
      regimen.&#xD;
&#xD;
      Subgroup 4. Progression after high-dose chemotherapy. Patients with progressive disease&#xD;
      within 3 months of high-dose chemotherapy are not allowed.&#xD;
&#xD;
      Performance Status: ECOG performance status 0, 1, 2&#xD;
&#xD;
      Life expectancy: Not specified&#xD;
&#xD;
      Hematopoietic:·&#xD;
&#xD;
        -  ANC ≥ 1,000/mm3·&#xD;
&#xD;
        -  Platelets ≥ 100,000/mm3&#xD;
&#xD;
      Hepatic:·&#xD;
&#xD;
        -  Total bilirubin ≤ 2.0 x ULN·&#xD;
&#xD;
        -  ALT and AST ≤ 3 x ULN unless lymphoma involves the liver on CT scan then AST and ALT can&#xD;
           be &lt; 5 x ULN&#xD;
&#xD;
      Renal:·&#xD;
&#xD;
        -  Serum creatinine ≤ 2.0 mg/dl (except for patients on dialysis)&#xD;
&#xD;
      Cardiovascular:·&#xD;
&#xD;
        -  Not specified&#xD;
&#xD;
      Pulmonary:·&#xD;
&#xD;
        -  Not specified&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated due to lack of response at the first efficacy analysis&#xD;
  </why_stopped>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>· Evaluate response rates to the rituximab plus gemcitabine treatment combination in patients with relapsed or refractory DLBCL.</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>· Evaluate toxicity, time to progression and overall survival.</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Lymphoma, B-Cell</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab + Gemcitabine for Relapsed or Refractory Diffuse Large B-Cell Lymphoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab 375 mg/m2, day 1 of 21 day cycle</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine 1000 mg/m2, days 1 and 8 of 21 day cycle</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy-proven DLBCL which meet the criteria of any of the 4 subgroups&#xD;
&#xD;
          -  Transformed DLBCL from a previous indolent NHL which meet the criteria of any of the 4&#xD;
             subgroups and have received at least one standard chemotherapy regimen for aggressive&#xD;
             NHL or a biopsy upon progression of disease has been obtained to confirm the presence&#xD;
             of DLBCL. The concomitant presence of a component of low grade lymphoma will NOT&#xD;
             exclude participation&#xD;
&#xD;
          -  Measurable disease per Standardized Response Criteria for Non-Hodgkin's Lymphoma&#xD;
&#xD;
          -  Prior gemcitabine therapy is allowed.&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No history of life-threatening reactions to rituximab.&#xD;
&#xD;
          -  No history of gemcitabine intolerance; prior gemcitabine therapy is allowed.&#xD;
&#xD;
          -  No history of malignancy in the last 5 years (basal cell carcinoma of the skin&#xD;
             excluded).&#xD;
&#xD;
          -  No central nervous system or cerebrospinal fluid involvement&#xD;
&#xD;
          -  No other investigational drugs received within 30 days prior to being registered for&#xD;
             protocol therapy.&#xD;
&#xD;
          -  No active infections.&#xD;
&#xD;
          -  No current breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Robertson, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Hoosier Oncology Group, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Elkhart Clinic</name>
      <address>
        <city>Elkhart</city>
        <state>Indiana</state>
        <zip>46515</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Associates of SW Indiana</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Oncology &amp; Hematology, Inc</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quality Cancer Center (MCGOP)</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer Care, Inc., P.C.</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Indiana Cancer Research Consortium</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Medical Group</name>
      <address>
        <city>Terre Haute</city>
        <state>Indiana</state>
        <zip>47802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP&amp;S Clinic</name>
      <address>
        <city>Terre Haute</city>
        <state>Indiana</state>
        <zip>47804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://hoosieroncologygroup.org/</url>
    <description>Hoosier Oncology Group Home Page</description>
  </link>
  <verification_date>April 2011</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>April 28, 2011</last_update_submitted>
  <last_update_submitted_qc>April 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>Michael Robertson, M.D.</name_title>
    <organization>Hoosier Oncology Group</organization>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

